Huang Wei-Chiao, Deng Bingbing, Seffouh Amal, Ortega Joaquin, Long Carole A, Suresh Ragavan V, He Xuedan, Miura Kazutoyo, Lee Shwu-Maan, Wu Yimin, Lovell Jonathan F
1Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260 USA.
2Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852 USA.
NPJ Vaccines. 2020 Mar 18;5(1):23. doi: 10.1038/s41541-020-0173-x. eCollection 2020.
Pfs230 is a malaria transmission-blocking antigen candidate, expressed on the surface of gametocytes. A recombinant, his-tagged Pfs230 fragment (Pfs230C1; amino acids 443-731) formed serum-stable particles upon incubation with liposomes containing cobalt-porphyrin-phospholipid (CoPoP). In mice, immunization with Pfs230C1, admixed with the adjuvants Alum, Montanide ISA720 or CoPoP liposomes (also containing synthetic monophosphoryl lipid A; PHAD), resulted in elicitation of IgG antibodies, but only those induced with CoPoP/PHAD or ISA720 strongly reduced parasite transmission. Immunization with micrograms of Pfs230C1 adjuvanted with identical liposomes lacking cobalt (that did not induce particle formation) or Alum was less effective than immunization with nanograms of Pfs230C1 with CoPoP/PHAD. CoPoP/PHAD and ISA720 adjuvants induced antibodies with similar Pfs230C1 avidity but higher IgG2-to-IgG1 ratios than Alum, which likely contributed to enhanced functional activity. Unlike prior work with another transmission-blocking antigen (Pfs25), Pfs230C1 was found to be effectively taken up by antigen-presenting cells without particle formation. The anti-Pfs230C1 IgG response was durable in mice for 250 days following immunization with CoPoP/PHAD, as were antibody avidity and elevated IgG2-to-IgG1 ratios. Immunization of rabbits with 20 µg Pfs230C1 admixed with CoPoP/PHAD elicited antibodies that inhibited parasite transmission. Taken together, these results show that liposomes containing CoPoP and PHAD are an effective vaccine adjuvant platform for recombinant malaria transmission blocking antigens.
Pfs230是一种疟疾传播阻断抗原候选物,在配子体表面表达。一种重组的、带有组氨酸标签的Pfs230片段(Pfs230C1;氨基酸443 - 731)与含有钴卟啉 - 磷脂(CoPoP)的脂质体孵育后形成血清稳定颗粒。在小鼠中,用Pfs230C1与佐剂明矾、Montanide ISA720或CoPoP脂质体(也含有合成单磷酰脂质A;PHAD)混合免疫,可诱导产生IgG抗体,但只有用CoPoP/PHAD或ISA720诱导产生的抗体能强烈降低寄生虫传播。用微克级的Pfs230C1与缺乏钴的相同脂质体(不诱导颗粒形成)或明矾佐剂免疫,效果不如用纳克级的Pfs230C1与CoPoP/PHAD免疫。CoPoP/PHAD和ISA720佐剂诱导的抗体对Pfs230C1的亲和力相似,但IgG2与IgG1的比值高于明矾,这可能有助于增强功能活性。与先前对另一种传播阻断抗原(Pfs25)的研究不同,发现Pfs230C1在不形成颗粒的情况下能被抗原呈递细胞有效摄取。用CoPoP/PHAD免疫小鼠后,抗Pfs230C1 IgG反应在250天内持续存在,抗体亲和力和升高的IgG2与IgG1比值也是如此。用20μg Pfs230C1与CoPoP/PHAD混合免疫兔子可诱导产生抑制寄生虫传播的抗体。综上所述,这些结果表明含有CoPoP和PHAD的脂质体是重组疟疾传播阻断抗原的有效疫苗佐剂平台。